Figure 2.
Avadomide effects signaling pathways and immune cell infiltration in DLBCL tumors. (A) RNA sequencing with immune cell deconvolution performed on screening and on-treatment (C1D10/15) biopsy specimens, showing enrichment/depletion relative to screening biopsy. (B) Cellular composition in paired tumor biopsy specimens by immunohistochemistry. Original magnification, ×20. (C) Intratumoral cell counts in screening vs on-treatment biopsy specimens by immunohistochemistry (CD20+ B cells; CD3+ T cells; CD163+ macrophages; CD56+ NK cells). DAPI, 4′,6-diamidino-2-phenylindole.

Avadomide effects signaling pathways and immune cell infiltration in DLBCL tumors. (A) RNA sequencing with immune cell deconvolution performed on screening and on-treatment (C1D10/15) biopsy specimens, showing enrichment/depletion relative to screening biopsy. (B) Cellular composition in paired tumor biopsy specimens by immunohistochemistry. Original magnification, ×20. (C) Intratumoral cell counts in screening vs on-treatment biopsy specimens by immunohistochemistry (CD20+ B cells; CD3+ T cells; CD163+ macrophages; CD56+ NK cells). DAPI, 4′,6-diamidino-2-phenylindole.

Close Modal

or Create an Account

Close Modal
Close Modal